FLT3 inhibition upregulates OCT4/NANOG to promote maintenance and TKI resistance of FLT3-ITD+ acute myeloid leukemia

FLT3 inhibition upregulates OCT4/NANOG to promote maintenance and TKI resistance of FLT3-ITD+ acute myeloid leukemia

Abstract Up to 30% of acute myeloid leukemia (AML) patients face unfavorable outcomes due to the FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation. Although FLT3 inhibitors show encouraging outcomes in treatment, they fail to eliminate leukemia stem cells, the ori...

Full description

Saved in:
Bibliographic Details
Main Authors: Qi Zhou, Zijian Li, Pingping Zhao, Yongyu Guan, Huiyuan Chu, Yaming Xi
Format: Article
Language:English
Published: Nature Publishing Group 2025-03-01
Series:Oncogenesis
Online Access:https://doi.org/10.1038/s41389-025-00553-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items